Portola Pharmaceuticals, Inc. (PTLA) Is At $44.41 Formed Wedge; Balyasny Asset Management Lowered Pioneer Energy Services (PES) Stake

Balyasny Asset Management Llc decreased Pioneer Energy Services Corp (PES) stake by 13.19% reported in 2017Q3 SEC filing. Balyasny Asset Management Llc sold 275,531 shares as Pioneer Energy Services Corp (PES)’s stock declined 51.26%. The Balyasny Asset Management Llc holds 1.81 million shares with $4.62M value, down from 2.09M last quarter. Pioneer Energy Services Corp now has $212.37 million valuation. The stock decreased 1.79% or $0.05 during the last trading session, reaching $2.75. About 1.02 million shares traded or 17.61% up from the average. Pioneer Energy Services Corp. (NYSE:PES) has risen 5.07% since February 10, 2017 and is uptrending. It has underperformed by 11.63% the S&P500.

Portola Pharmaceuticals, Inc. (PTLA) formed wedge down with $41.75 target or 6.00% below today’s $44.41 share price. Portola Pharmaceuticals, Inc. (PTLA) has $2.90 billion valuation. The stock decreased 0.49% or $0.22 during the last trading session, reaching $44.41. About 1.29M shares traded or 41.25% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 10, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Investors sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold Portola Pharmaceuticals, Inc. shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Harvey Cap Mngmt invested in 143,730 shares or 3.13% of the stock. Sg Americas Secs Lc invested 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Jpmorgan Chase Com holds 744,702 shares. 35,450 were accumulated by Hartwell J M Partnership. Natl Bank Of Montreal Can accumulated 535 shares or 0% of the stock. Cadian Mgmt Lp stated it has 1.17M shares or 2.95% of all its holdings. Alps Incorporated reported 0.02% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Tortoise Inv Mngmt Limited Liability Com holds 164 shares. Parametric Portfolio Associate Limited Liability, Washington-based fund reported 38,664 shares. Bnp Paribas Arbitrage holds 0% or 6,878 shares in its portfolio. Principal Fincl Grp holds 0% or 62,129 shares. Blume Capital Mgmt holds 0.03% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 1,000 shares. Fmr Ltd owns 0.04% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 5.76M shares. Pinnacle Assoc has 492,381 shares. Covington Cap Mngmt stated it has 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $75.67’s average target is 70.39% above currents $44.41 stock price. Portola Pharmaceuticals had 33 analyst reports since August 5, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by Cowen & Co with “Buy”. The company was maintained on Thursday, August 10 by Oppenheimer. Oppenheimer maintained it with “Buy” rating and $80.0 target in Wednesday, December 13 report. On Thursday, December 28 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Oppenheimer on Monday, June 26 with “Buy”. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Wednesday, September 20 with “Buy” rating. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Monday, August 28 by Oppenheimer. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Goldman Sachs on Friday, December 18. The rating was maintained by Citigroup on Monday, June 26 with “Buy”. As per Friday, August 19, the company rating was maintained by Credit Suisse.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on February, 27. They expect $-1.52 EPS, down 60.00% or $0.57 from last year’s $-0.95 per share. After $-1.41 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.80% negative EPS growth.

Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $563,950 activity. $563,950 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) was sold by Wolff Henry Ward on Friday, December 15.

Among 14 analysts covering Pioneer Energy (NYSE:PES), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. Pioneer Energy had 32 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Wells Fargo on Tuesday, September 1. As per Wednesday, June 21, the company rating was downgraded by Seaport Global. The firm has “Hold” rating by Jefferies given on Monday, July 11. The company was upgraded on Friday, December 16 by Goldman Sachs. The stock of Pioneer Energy Services Corp. (NYSE:PES) has “Hold” rating given on Monday, October 16 by Wells Fargo. The firm earned “Overweight” rating on Wednesday, June 29 by Simmons & Co. The stock of Pioneer Energy Services Corp. (NYSE:PES) earned “Buy” rating by DA Davidson on Thursday, September 15. Deutsche Bank maintained Pioneer Energy Services Corp. (NYSE:PES) on Friday, July 31 with “Hold” rating. Wunderlich upgraded Pioneer Energy Services Corp. (NYSE:PES) on Monday, December 12 to “Buy” rating. The firm has “Mkt Perform” rating given on Wednesday, November 2 by Raymond James.